Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
· seekingalpha.com
Argenx (ARGX) stock surged after a successful Vyvgart trial in autoimmune myositis.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...